January 23, 2017 1:08 AM ET

Biotechnology

Company Overview of Avelas BioSciences, Inc.

Company Overview

Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

11099 North Torrey Pines Road

Suite 290

La Jolla, CA 92037

United States

Founded in 2008

Phone:

858-750-4700

Fax:

858-750-4701

Key Executives for Avelas BioSciences, Inc.

Chief Executive Officer, President and Director
Age: 40
Co-Founder and Research Collaborator
Age: 64
Vice President of Clinical Affairs
Clinical Advisor
Age: 47
Compensation as of Fiscal Year 2016.

Avelas BioSciences, Inc. Key Developments

Avelas Presents Phase 1b Clinical Trial Data for AVB-620

Avelas Biosciences, Inc. presented clinical trial data from the company's recently completed Phase 1b study in breast cancer patients utilizing investigational drug product AVB-620, at the San Antonio Breast Cancer Symposium. Jonathan Unkart, M.D., resident physician at Moores Cancer Center at UC San Diego Health, delivered the presentation titled "Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: A first-in-human phase 1 study allows tumors to be visualized in the operating room" on behalf of himself and senior author Anne Wallace, M.D., Director of the Comprehensive Breast Health Center at Moores Cancer Center. The study represents the first-in-human experience with investigational drug product AVB-620, an activatable fluorescent peptide which is a potential adjunct in surgery for identifying tumors in real time. Dr. Unkart provided details on the safety and early results on proof-of-concept for the use of AVB-620 in identifying breast tumors during surgery. Specifically, no drug-related adverse events were noted in the trial and AVB-620 was able to achieve separation of tumor from adjacent tissues using a fluorescent image in both primary tumors and in lymph nodes.

Avelas BioSciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 02:00 PM

Avelas BioSciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 02:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.

Avelas BioSciences, Inc. Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial

Avelas Biosciences, Inc. announced the completion of patient enrollment in its Phase 1b clinical trial for AVB-620, a surgical marker, in women with primary, non-recurrent breast cancer undergoing surgery. Avelas will announce data from the trial at a future medical meeting. AVB-620 Phase 1b Clinical Program: Fifteen patients were enrolled in the initial dose-escalation portion of the Phase 1b trial, the purpose of which was to evaluate safety and pharmacokinetics and to determine the dose for additional imaging analysis in the second stage of the study. Interim analysis showed no toxicity issues and identified a preferred dose to take forward into the expansion phase of the trial. A total of 12 additional patients have been enrolled in the dose-expansion stage of the trial, where the focus remains on safety, pharmacokinetics, and the timing of imaging after AVB-620 administration. The company expects to announce data from its completed Phase 1b trial later 2016. AVB-620 is an intravenously administered in vivo fluorescent protease-activatable peptide that detects, labels, and visualizes cancer. The initial potential use for AVB-620 is the intraoperative identification of primary tumor extent and metastatic lymph nodes in breast cancer patients. AVB-620 displayed outstanding preclinical data with sensitivity of greater than 95% in preclinical breast cancer models and ex vivo analysis of human breast cancer tissue.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 18, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Avelas BioSciences, Inc., please visit www.avelasbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.